char = B;code = 66
Beta2-microglobulin-selective adsorbent column (Lixelle) for the treatment of dialysis-related amyloidosis.char = L;code = 76
Publication: Ther Apher Dial 2003 Feb ;7(1)::104-7.
Publication Date: 2003 Feb
Study Author(s): Suzuki, Kazuo;Shimazaki, Masami;Kutsuki, Hidetoshi;
Institution: Medical Devices Division, Kaneka Corporation, Osaka, Japan.
[email protected]
Shortcut link to this study:
Lixelle is a direct hemoperfusion-type adsorbent column developed for selective elimination of beta2-microglobulin (beta2-m) from the circulating blood of patients with dialysis-related amyloidosis (DRA). Lixelle S-35, that has a column volume of 350 mL, efficiently eliminates beta2-m and improves symptoms of DRA such as joint pain and nocturnal awakening. The performance of Lixelle S-15, that has a column volume of 150 mL, is dependent on the dialysis membrane used in combination with the adsorbent column in a hemodialysis circuit. The combination of S-15 and a dialysis membrane with a high beta2-m clearance eliminates an amount of beta2-m that is nearly equal to the amount removed by using S-35. Treatment with S-15 for 6 months improved joint pain with an efficacy similar to that observed when using S-35. The major adverse effects were hypotension and decrease in hematocrit, and these incidences were much less in S-15 compared to S-35.
PMID: 12921124
How is this determined?
